Moderna's 367% Melt-Up: How One Melanoma Trial Rewired the Market's View of mRNA
Published on 08/23/2026 at 17:30 | Redaktion boerse-global.de
The stock market has a short memory, but Moderna's recent run is forcing even the most jaded traders to pay attention. A single Phase-3 readout in melanoma has transformed the biotech's narrative from pandemic-era has-been to oncology pioneer — and the numbers behind the move are staggering.
Shares have climbed 367 percent since the start of the year, with the rally accelerating dramatically after Moderna and partner Merck & Co. announced on August 19 that their personalized mRNA cancer therapy, intismeran (mRNA-4157/V940), hit its primary endpoint in the INTerpath-001 study. The trial, which enrolled more than 1,100 patients with resected high-risk melanoma, showed the combination of intismeran and Merck's Keytruda extended relapse-free survival. A key secondary endpoint — metastasis-free survival — was also met.
The result marks the first positive late-stage readout ever for an mRNA cancer vaccine, a milestone that has fundamentally shifted how Wall Street views the platform's potential beyond infectious disease.
A Rally That Feeds on Itself
The market's response was immediate and violent. On Friday alone, the stock jumped 8.6 percent, closing at 123.92 euros. Over seven days, the gain compounds to 127 percent; over thirty days, 143 percent. The move has been amplified by a short squeeze — roughly 12 percent of the free float was sold short, according to reports, forcing bears to cover as the price climbed.
The technical picture tells its own story. The relative strength index sits at 71.3, deep in overbought territory, while annualized volatility has reached an eye-watering 516 percent. The stock now trades 17 percent below its 52-week high of 149.62 euros, reached just this week — but stands 540 percent above its November low of 19.36 euros.
Should investors sell immediately? Or is it worth buying Moderna?
Wall Street Scrambles to Catch Up
The analyst community has responded with a flurry of target revisions that reflect both the significance of the data and the uncertainty that remains. William Blair upgraded the stock from "Market Perform" to "Outperform," calling the cancer vaccine data a turning point for the entire mRNA platform. Goldman Sachs lifted its price target from 67 to 120 dollars while maintaining a "Neutral" rating. Loop Capital set a new target of 135 dollars.
Even JPMorgan Chase, which raised its target from 40 to 77 dollars while keeping an "Underweight" stance, implicitly acknowledged that the clinical data has altered the fundamental picture. The range of targets — from skeptical to enthusiastic — underscores how much remains unknown.
Institutions Move In
The rally isn't just retail speculation. BlackRock disclosed on August 20 a new position of roughly 30.6 million shares, valued at around 2.14 billion dollars, representing a 7.66 percent stake. Earlier in the month, Capital World Investors revealed a passive holding of 5.6 percent. These inflows suggest institutional investors are participating in the re-rating, not just short-term traders.
The Manufacturing Question
For all the enthusiasm, significant hurdles remain. Reuters has reported that Moderna acknowledged the complexity and cost of manufacturing personalized vaccines at scale — each dose must be tailored to an individual patient, a logistical challenge that directly affects the melanoma program's commercial viability.
The company's own president, Stephen Hoge, has indicated that additional trial results across other cancer types are expected within the next one to two years. The combination therapy is already being tested in mid-stage studies for bladder and kidney cancer, with early-stage trials underway for pancreatic and stomach cancer.
A Business Still in Transition
The oncology breakthrough arrives alongside other pipeline progress. The FDA approved mFLUSIVA on August 5, the company's first mRNA-based influenza vaccine and only its second commercial product. Moderna also initiated a Phase-1 trial for mRNA-1469, a candidate targeting the Bundibugyo ebolavirus.
Moderna at a turning point? This analysis reveals what investors need to know now.
Yet the underlying business remains loss-making. Second-quarter 2026 results showed revenue of 145 million dollars and a loss per share of 1.97 dollars — better than analyst estimates, but a reminder that the core operations are still far from profitable.
Two Truths at Once
The honest assessment may be that both narratives are simultaneously valid. The science has achieved a genuine milestone, validating mRNA's potential in oncology and opening a new chapter for the platform. But whether that translates into a sustainable, high-margin business depends on questions that only future data and manufacturing realities can answer.
For now, the market has chosen to believe in the vision. The full dataset and overall survival results are still pending, and analysts are waiting for those numbers before drawing broader conclusions about the commercial outlook. Until then, Moderna's stock remains a bet on promise — a high-wire act where every piece of news from the regulatory process could send the shares in either direction.
Ad
Moderna Stock: New Analysis - 23 August
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
